Art. -Nr.: HY-150231

SU056

Name: SU056
Brand: MedChemExpress
SKU: HY-150231
Price: 60.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

SU056 is a YB-1 inhibitor. SU056 induces cell-cycle arrest, apoptosis, and inhibits cell migration in ovarian cancer cells. SU056 interacts with YB-1 and inhibits and its associated downstream proteins and pathways. SU056 can enhance the cytotoxic effects of Paclitaxel (HY-B0015).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.77%
CAS. Nr.: 2376580-08-2
Formel: C₂₀H₁₆FNO₅
Molecular Weight:369.34

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

SU056 Chemical Structure

CAS. Nr.: 2376580-08-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

YB-1^[1]

In Vitro

SU056 (0-10 μM approximately, 48 h) inhibits cell growth in OVCAR3/4/5/8, SKOV3 and ID8 cells^[1].
SU056 (1 μM, 5-8 days) inhibits colony formation in a dose-dependent manner in OVCAR-8 and ID8 cells^[1].
SU056 (1-5 μM, 6 h) arrests OVCAR8, SKOV3, and ID8 cells in the sub-G1 and G1 phases^[1].
SU056 (0-1 μM, 12 h) inhibits cell migration in OVCAR8, SKOV3, and ID8 cells^[1].
SU056 (0-5 μM, 24 h) induces apoptotic cell death in OVCAR8, SKOV3, and ID8 cells^[1].
SU056 (1-5 μM, 12 h) inhibited the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells^[1].
SU056 (0.1, 0.5, and 1 μM, 48 h) enhances the cytotoxic effects of Paclitaxel (HY-B0015) (0.1, 0.5, and 1 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

OVCAR3/4/5/8, SKOV3 and ID8 cells
Concentration:

0-10 μM approximately
Incubation Time:

48 h
Result:

Inhibited cell growth with IC₅₀ values of 1.27, 6.8, 4.33, 3.18, 1.73, 3.75 μM.

Cell Migration Assay ^[1]

Cell Line:

OVCAR8, SKOV3, and ID8 cells
Concentration:

0, 0.5, 1 μM
Incubation Time:

12 h
Result:

Dose-dependently inhibited cell migration.

Western Blot Analysis^[1]

Cell Line:

OVCAR8 cell
Concentration:

1-5 μM
Incubation Time:

12 h
Result:

Dose-dependently inhibited the YB-1, TMSB10, SUMO2, and PMSB2 proteins.

In Vivo

SU056 (20 mg/kg, i.p.) inhibits tumor growth in mice implanted with ID8 cells^[1].
SU056 (10 mg/kg, i.p., daily) combined with Paclitaxel (HY-B0015) (5 mg/kg, weekly, i.p.) shows a much greater reduction in OC tumor growth in immunodeficiency mice implanted with OVCAR8 OC tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice implanted (s.c.) with luciferase-expressing ID8 cells^[1]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Reduced the tumor weight by 2-fold, and is well-tolerated.
Reduced the lung metastases.
Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample).

Related Protocols :

Chemical Information

CAS. Nr. 2376580-08-2
Appearance Solid
Molecular Weight 369.34
Formel C₂₀H₁₆FNO₅
Color White to off-white
SMILES

O=C1OCC2=C1C(C3=CC4=C(C=C3N2CCO)OCO4)C5=CC(F)=CC=C5
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (2)

All Cell Imaging/Staining

Sort by:

Journal Impact Factor

Int J Mol Sci

Downregulation of IL-8 and IL-10 by LRRC8A Inhibition through the NOX2-Nrf2-CEBPB Transcriptional Axis in THP-1-Derived M2 Macrophages. [Abstract]

2024 Sep 5;25(17):9612. PMID: 39273558
J Virol

YBX1 is required for assembly of viral replication complexes of chikungunya virus and replication of multiple alphaviruses. [Abstract]

2025 Feb 25;99(2):e0201524. PMID: 39745458

SU056 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Feb 25;99(2):e0201524. [Abstract]

SU056 (0.1-0.5 μM; 12 h) inhibited CHIKV replication in BHK-21 cells at a dose-dependent manner.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (135.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7075 mL

13.5377 mL

27.0753 mL

5 mM

0.5415 mL

2.7075 mL

5.4151 mL

10 mM

0.2708 mL

1.3538 mL

2.7075 mL

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (6.77 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (6.77 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL. If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tailor D, et al. Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chem Biol. 2021 Aug 19;28(8):1206-1220.e6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7075 mL	13.5377 mL	27.0753 mL	67.6883 mL
	5 mM	0.5415 mL	2.7075 mL	5.4151 mL	13.5377 mL
	10 mM	0.2708 mL	1.3538 mL	2.7075 mL	6.7688 mL
	15 mM	0.1805 mL	0.9025 mL	1.8050 mL	4.5126 mL
	20 mM	0.1354 mL	0.6769 mL	1.3538 mL	3.3844 mL
	25 mM	0.1083 mL	0.5415 mL	1.0830 mL	2.7075 mL
	30 mM	0.0903 mL	0.4513 mL	0.9025 mL	2.2563 mL
	40 mM	0.0677 mL	0.3384 mL	0.6769 mL	1.6922 mL
	50 mM	0.0542 mL	0.2708 mL	0.5415 mL	1.3538 mL
	60 mM	0.0451 mL	0.2256 mL	0.4513 mL	1.1281 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8461 mL
	100 mM	0.0271 mL	0.1354 mL	0.2708 mL	0.6769 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SU056

Publications Citing Use of MedChemExpress (MCE) SU056